Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Cytotoxic small‐molecule drugs have a major influence on the fate of antibody–drug conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable while linked to ADCs, kill the targeted tumor cell upon internalization and release from the ADCs, and maintain its activity in multidrug‐resistant tumor cells. Lessons learned from successful and failed experiences in ADC development resulted in remarkable progress in the discovery and development of novel highly potent small molecules. A better understanding of such small‐molecule drugs is important for development of effective ADCs. The present review discusses requirements making a payload appropriate for antitumor ADCs and focuses on the main characteristics of commonly‐used cytotoxic payloads that showed acceptable results in clinical trials. In addition, the present study represents emerging trends and recent advances of payloads used in ADCs currently under clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“Importantly, tumor cells frequently display deficiency in one or more related DNA repair pathways, therefore resulting in selective antitumor activities (Farmer et al., 2005; Mantaj et al., 2016).”
BackgroundTargeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“More importantly, drug transporters mainly facilitate the efflux of hydrophobic compounds (Szakacs, Paterson, Ludwig, Booth ‐ Genthe, & Gottesman, 2006; Takeshita et al., 2009).”
BackgroundStrategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930 · cited 13×
“The payload potency was improved by using new drugs, including microtubule ‐ targeting agents (maytansinoids and auristatins) or DNA ‐ targeting agents (calicheamicins) that showed 100 – 1,000 ‐ fold more potency as compared with previously ‐ used payloads (Teicher & Chari, 2011).”
BackgroundInfluentialTaxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
Abal, M., Andreu, J., & Barasoain, I. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481967 · Cited by 383 · cited 1×
“…paclitaxel and docetaxel) are examples of microtubule ‐ targeting agents, acting by disrupting normal microtubule formation and stabilizing altered microtubule structures, respectively, in a way that interferes with normal microtubular degradation during mitosis (Abal, Andreu, & Barasoain, 2003).”
BackgroundLuesch, H., Moore, R. E., Paul, V. J., Mooberry, S. L., & Corbett, T. H. (2001) · Journal of Natural Products · doi:10.1021/np010049y · Cited by 378 · cited 1×
“…peptides from the shell ‐ less mollusk Dolabella auricularia (sea hare): dolastatins 1 – 15, showing the ability to strongly kill cancer cell lines (Anderl et al., 2013; Luesch, Moore, Paul, Mooberry, & Corbett, 2001; Pettit et al., 1981, 1982, 1987, 1987, 1989a, 1989b, 1989c, 1990, 1993).”
BackgroundDolastatin 10, a powerful cytostatic peptide derived from a marine animal
Bai, R., Petit, G. R., & Hamel, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90613-p · Cited by 321
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Mantaj, J., Jackson, P. J. M., Rahman, K. M., & Thurston, D. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201510610 · Cited by 262
Gregson, S. J., Howard, P. W., Hartley, J. A., Brooks, N. A., Adams, L. J., Jenkins, T. C., Kelland, L. R., & Thurston, D. E. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001064n · Cited by 202 · cited 2×
“This makes PBD dimers a promising payload for use in ADC and interesting mechanism of action (Gregson et al., 2001).”
BackgroundNovel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Nakada, T., Masuda, T., Naito, H., Yoshida, M., Ashida, S., Morita, K., Miyazaki, H., Kasuya, Y., Ogitani, Y., Yamaguchi, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.020 · Cited by 172
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Payload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257
Yao, H.-P., Zhao, H., Hudson, R., Tong, X.-M., & Wang, M.-H. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.012 · Cited by 70
Metadata
- Authors
- Yaghoubi, S., Karimi, M. H., Lotfinia, M., Gharibi, T., Mahi‐Birjand, M., Kavi, E., Hosseini, F., Sineh Sepehr, K., Khatami, M., Bagheri, N., & Abdollahpour‐Alitappeh, M.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2019-06-18
- Volume
- 235
- Issue
- 1
- Pages
- 31-64
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2950613960
- Cited by
- 152
- References
- 10
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. https://app.cochat.ai/papers/10.1002/jcp.28967
- The paper
- Yaghoubi, S., Karimi, M. H., Lotfinia, M., Gharibi, T., Mahi‐Birjand, M., Kavi, E., Hosseini, F., Sineh Sepehr, K., Khatami, M., Bagheri, N., & Abdollahpour‐Alitappeh, M. (2020). Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.28967
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.